MS Pharma has struck a deal with Bioeq to gain rights in the MENA region to its FYB201 proposed biosimilar ranibizumab rival to Lucentis, developed in collaboration with Formycon.
Jordan-based firm MS Pharma has announced a deal with Bioeq that will give it exclusive rights in the Middle East and North Africa region to the FYB201 proposed biosimilar rival to Lucentis (ranibizumab) that has been developed through a partnership between Bioeq and Formycon.
Under the terms of the agreement, MS Pharma will be responsible for registering and commercializing FYB201, with the company indicating...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
